GlaxoSmithKline has issued a voluntary recall for two lots of migraine medication Imitrex.
The recall of Lots C637078 and C632842 was made in consultation with Health Canada.
The medication comes in pre-filled syringes with a sterile needle for injection.
Health Canada says needles in the affected lots may be protruding through their protective plastic shields and are no longer sterile.
There is a potential risk of infection to consumers when using the product because of the protrusion.
For more details on the Imitrex injection recall, visit the Health Canada website.